


# Translational Regenerative Medicine

### Edited by

Anthony Atala, MD Julie G. Allickson, PhD

Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, USA







Academic Press is an imprint of Elsevier 32 Jamestown Road, London NW1 7BY, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK

Copyright © 2015 Elsevier Inc. All rights reserved. Except Chapter 1 which is in the public domain.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-12-410396-2

#### **British Library Cataloguing in Publication Data**

A catalogue record for this book is available from the British Library

#### Library of Congress Catalog Number

A catalog record for this book is available from the Library of Congress

For information on all Academic Press publications visit our website at http://store.elsevier.com/

Typeset by TNQ Books and Journals www.tnq.co.in



# Translational Regenerative Medicine

# This textbook is dedicated to Katherine, Christopher, and Zachary.

Anthony Atala

This textbook is dedicated to Brandon and Jason.

Julie Allickson

## Contributors

- Mehran Abolbashari Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Jaimo Ahn Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- Salem Akel St. Louis Cord Blood Bank & Cellular Therapy Laboratory, SSM Cardinal Glennon Children's Medical Center, St. Louis, MO, USA; Department of Pediatric, Saint Louis University School of Medicine, St. Louis, MO, USA
- Julie G. Allickson Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
- Graça Almeida-Porada Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
- **Judith Arcidiacono** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Anthony Atala Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
- **Patrick Au** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Danielle Aufiero The Orthohealing Center and The Orthobiologic Institute (TOBI), Los Angeles, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Orthohealing Center, Los Angeles, CA, USA; Western University of Health Sciences, Pomona, CA, USA; Touro University, Vallejo, CA, USA
- Pedro M. Baptista Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA; University of Zaragoza, Zaragoza, Spain; IIS Aragón, CIBERehd, Zaragoza, Spain; Aragon Health Sciences Institute (IACS), Zaragoza, Spain
- Ronnda L. Bartel Aastrom Biosciences, Ann Arbor, MI
- **Amelia Bartholomew** University of Illinois, Department of Surgery, Chicago, IL, USA

- Elona Baum Coherus BioSciences, Inc. Redwood City, California; formerly California Institute for Regenerative Medicine, San Francisco, California, USA
- Angie Botto-van Bemden Musculoskeletal Research International (MRI), Ft. Lauderdale, FL, USA; Clinical Research Experts (CRE), Ft. Lauderdale, FL, USA; Florida International University, Miami, FL, USA
- Khalil N. Bitar Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA; Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Winston-Salem, NC, USA
- Lynne Boxer Center for Veterinary Medicine, FDA, Rockville, MD, USA
- Matthew P. Brown Founder Shama Consulting
- **Heather L. Brown** Vice President Scientific Medical Affairs, Cord Blood Registry, San Bruno, CA, USA
- **Stephanie J. Bryant** Department of Chemical and Biological Engineering, College of Engineering and Applied Science, University of Colorado, Boulder, CO, USA
- Pedro P. Carvalho 3B's Research Group, Department of Polymer Engineering, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal; ICVS/3B's – PT Government Associate Laboratory, Braga/Guimarães, Portugal
- Prafulla Chandra Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
- John R. Chapman President of Stem Cell Partners & Adjunct Professor of Biology, California State University Sacramento, USA
- Shreyasi Das Sanford-Burnham Medical Research Institute, San Diego, CA, USA
- **Daniel B. Deegan** Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA
- **Abritee Dhal** Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA

- Albert D. Donnenberg University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Division of Hematology/ Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
- Matthew B. Durdy Cell Therapy Catapult, Guy's Hospital, Great Maze Pond, London, UK
- **Charles N. Durfor** Center for Devices and Radiological Health, FDA, Silver Spring, MD, USA
- Elazer R. Edelman Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- **Donald Fink** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Steven Fischkoff Celgene Cellular Therapeutics, Warren, NJ, USA
- Joyce L. Frey-Vasconcells Frey-Vasconcells Consulting, LLC, Sykesville, MD, USA
- **Tobias Führmann** Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada
- Carmen Gacchina Johnson Commissioner's Fellowship Program, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, MD, USA; Center for Devices and Radiological Health, FDA, Silver Spring, MD, USA
- Or Gadish Harvard-MIT Program in Health Sciences and Technology, & Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA
- Sanjiv S. Gambhir Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, USA; Bioengineering, Materials Science & Engineering, Bio-X, Stanford University, Stanford, CA, USA
- Adrian P. Gee Center for Cell & Gene Therapy, Baylor College of Medicine, Houston, Texas, USA
- Manuela E. Gomes 3B's Research Group, Department of Polymer Engineering, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal; ICVS/3B's – PT Government Associate Laboratory, Braga/Guimarães, Portugal
- Kurt D. Hankenson Department of Small Animal Clinical Sciences College of Veterinary Medicine; and Department of Physiology, Colleges of Natural Sciences and Osteopathic Medicine
- Robert J. Hariri Celgene Cellular Therapeutics, Warren, NJ, USA

- **Heather C. Hatcher** Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA
- **Mohammad Heidaran** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Ralf Huss University of Munich, Munich, Germany; Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA; Apceth GmbH & Co. KG, Munich, Germany; Definiens AG, Munich, Germany
- **John Hyde** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Yoshito Ikada Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
- Deepak Jain Bioprocess Research & Development, Manufacturing and Technical Operations, Tengion, Inc., Winston-Salem, NC, USA
- Paul A. Jain University of California-San Diego Medical Center, San Diego Veterans Affair Medical Center, San diego, CA, USA
- Jesse V. Jokerst Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, USA
- Philipp Jungebluth Department of Clinical Science, Intervention and Technology, Division of Ear, Nose and Throat, Advanced Center for Translational Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
- Eve Kandyba Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA; Department of Pathology, University of Southern California, Los Angeles, CA, USA
- **David S. Kaplan** Center for Devices and Radiological Health, FDA, Silver Spring, MD, USA
- Safa Karandish Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- **F. Kurtis Kasper** Department of Bioengineering, Rice University, Houston, TX, USA
- Sneha S. Kelkar Wake Forest-Virginia Tech School of Biomedical Engineering and Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, USA; Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA
- Norma Kenyon Diabetes Research Institute, Miami, FL, USA
- **Krzysztof Kobielak** Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA,

- USA; Department of Pathology, University of Southern California, Los Angeles, CA, USA
- Jesse Kramer Vice President Scientific Medical Affairs, Cord Blood Registry, San Bruno, CA, USA
- Sang Jin Lee Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Mark H. Lee Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Yvonne Leung Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA; Department of Pathology, University of Southern California, Los Angeles, CA, USA
- Mei Ling Lim Department of Clinical Science, Intervention and Technology, Division of Ear, Nose and Throat, Advanced Center for Translational Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
- **Neil J. Littman** California Institute for Regenerative Medicine, San Francisco, California, USA
- Paolo Macchiarini Department of Clinical Science, Intervention and Technology, Division of Ear, Nose and Throat, Advanced Center for Translational Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden
- Nafees N. Malik Cell Therapy Catapult, Guy's Hospital, Great Maze Pond, London, UK; Asklepian Consulting, Birmingham, UK; Institute of Biotechnology, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
- Brenda K. Mann SentrX Animal Care, Salt Lake City, UT, USA
- Kacey G. Marra Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; McGowan Institute of Regenerative Medicine, Pittsburgh, PA, USA
- Robert E. Marx Chief Division of Oral and Maxillofacial Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
- Lina Mastrangelo Sanford-Burnham Medical Research Institute, San Diego, CA, USA
- **Brent McCright** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- **Richard McFarland** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Michael Mendicino Commissioner's Fellowship Program, Office of the Commissioner, U.S. Food and Drug

- Administration, Silver Spring, MD, USA; Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- **Antonios G. Mikos** Department of Bioengineering, Rice University, Houston, TX, USA
- **Nikolaos Mitrousis** Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada
- Aaron M. Mohs Wake Forest-Virginia Tech School of Biomedical Engineering and Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, USA; Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest University Health Sciences, Winston-Salem, NC, USA
- Thomas Moore Founder Shama Consulting
- Emma C. Moran Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA
- Walter Niles Sanford-Burnham Medical Research Institute, San Diego, CA, USA
- Guoguang Niu Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston–Salem, NC, USA
- Masashi Nomi Department of Urology, Suma-Ku, Kobe Children's Hospital, Kobe, Japan
- **Tamara Nunez** University of Illinois, Department of Surgery, Chicago, IL, USA
- Robert Perry Athersys, Inc., Cleveland, Ohio, USA
- **Robert P. Pfotenhauer** Vice President Scientific Medical Affairs, Cord Blood Registry, San Bruno, CA, USA
- Christopher D. Porada Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
- **Kavitha Premenand** University of Illinois, Department of Surgery, Chicago, IL, USA
- **Glenn D. Prestwich** Department of Medicinal Chemistry, The University of Utah, Salt Lake City, Utah, USA
- Shreya Raghavan Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA; Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Winston-Salem, NC, USA
- Mahendra Rao NIH Center for Regenerative Medicine, Bethesda, MD, USA
- Anthony Ratcliffe Synthasome, Inc., San Diego, CA, USA
- Stephen Rego Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

- Rui L. Reis 3B's Research Group, Department of Polymer Engineering, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal; ICVS/3B's – PT Government Associate Laboratory, Braga/Guimarães, Portugal
- Ivan N. Rich HemoGenix, Inc, Colorado Springs, CO, USA
- Márcia T. Rodrigues 3B's Research Group, Department of Polymer Engineering, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal; ICVS/3B's PT Government Associate Laboratory, Braga/Guimarães, Portugal
- J. Peter Rubin Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; McGowan Institute of Regenerative Medicine, Pittsburgh, PA, USA
- Steven Sampson The Orthohealing Center and The Orthobiologic Institute (TOBI), Los Angeles, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Orthohealing Center, Los Angeles, CA, USA; Western University of Health Sciences, Pomona, CA, USA; Touro University, Vallejo, CA, USA
- Etai Sapoznik Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston–Salem, NC, USA; Virginia Tech Wake Forest University School of Biomedical Engineering and Sciences, Virginia Tech, Blacksburg, VA, USA
- John G. Sharp Department of Genetics, Cell Biology & Anatomy, University of Nebraska Medical Center, Omaha, NE, USA
- Molly S. Shoichet Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada; Department of Chemistry, University of Toronto, Toronto, ON, Canada; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada
- Daniel Skuk Neurosciences Division—Human Genetics, CHUQ Research Center—CHUL, Quebec, QC, Canada
- **Evan Y. Snyder** Sanford-Burnham Medical Research Institute, San Diego, CA, USA
- Shay Soker Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston–Salem, NC, USA; Virginia Tech Wake Forest University School of Biomedical Engineering and Sciences, Virginia Tech, Blacksburg, VA, USA
- Sita Somara Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
- **Tom Spencer** Process Development and Manufacturing, Tengion, Inc., Winston-Salem, NC, USA

- Suzanne Stewart Department of Clinical Studies-New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA, USA
- Premenand Sundivakkam University of Illinois Department of Surgery, Chicago, IL, USA
- **Erszebet Szilagyi** University of Illinois, Department of Surgery, Chicago, IL, USA
- **Alexander M. Tatara** Department of Bioengineering, Rice University, Houston, TX, USA
- **Brian Tobe** Sanford-Burnham Medical Research Institute, San Diego, CA, USA; Department of Psychiatry, Veterans Administration Medical Center, San Diego, CA, USA
- Jacques P. Tremblay Neurosciences Division—Human Genetics, CHUQ Research Center—CHUL, Quebec, QC, Canada
- Alan O. Trounson Richie Centre, Monash University, Monash Medical Centre, Clayton, Victoria, Australia
- **Anup Tuladhar** Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada
- **Lori Tull** Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- **Jolene E. Valentin** Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, PA, USA
- **Dipen Vyas** Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA
- **Zhan Wang** Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston–Salem, NC, USA
- Alicia Winquist Sanford-Burnham Medical Research Institute, San Diego, CA, USA
- Celia Witten Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
- Mark E.K. Wong Department of Oral and Maxillofacial Surgery, University of Texas Health Science Center at Houston, Houston, TX, USA
- James J. Yoo Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Diana Yoon Commissioner's Fellowship Program, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, MD, USA; Center for Devices and Radiological Health, FDA, Silver Spring, MD, USA
- Elie Zakhem Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
- Joao Paulo Zambon Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

## Contents

Co	ntribut	ors	xvii			Sterility Testing	23
						Mycoplasma Testing	24
ln	Introduction: Regenerative Medicine					Endotoxin Level Testing	24
						Genetic Stability	24
1.	The I	Landscape of Cell Tissues and Organs	3		Ш.	Standard Life Cycle of Banked	
	Maho	ndra Rao				Cell Therapy Product	24
	Walle	nura Nao				Biomaterial Collection	24
	J.	The Regenerative Medicine Field	3			Cell/Tissue Processing	25
	П.	Conclusions	7			Freezing	27
	Discla	nimer	8			Cryopreservation	29
	Refere	ences	8			Shipment	30
						Product Thaw/Infusion	30
					IV.	CT Facility	31
Se	ectio	n I				CT Facility Space Classification	
C	ell B	anking				and Environmental Control	31
		8			V.	Cleaning and Disinfection	32
2	Lanc	dscape of Cell Banking	13			Environmental Monitoring	33
	Luiic	seape of cell banking	13			Equipment	35
	Heath	ner C. Hatcher, Anthony Atala			VIII.	Critical Reagents and Supplies Management	36
	and Ju	ulie G. Allickson			Refe	rences	36
		Introduction: The Field of Cell Banking	13	4.		nical Development of Placental	
		Allogeneic and Autologous Cell Banking Recruitment	13 14		Mes	senchymal Stromal Cells	39
			14		Robe	ert J. Hariri and Steven Fischkoff	
	IV.	Regulations and Determination	14				
	V	of Regulatory Guidance Registration and Donor Eligibility	14			Conclusion	46
	٧.	Screening/Testing	15		Refe	rences	47
	VI	Current Good Tissue Practice (cGTP)	16	5	Trai	aslation of Pogoporative Medicine	
		Ethics (Personal Data, Health	10	٥.		nslation of Regenerative Medicine ducts Into the Clinic in the United	
	V.11.	Information, Genetic Analysis, Privately					40
		Banked Cells)	16		Stat	es: FDA Perspective	49
	VIII.	Financial Aspects	17		Marl	k H. Lee, Patrick Au, John Hyde, Carmen	
		The Role of Banking in Regenerative Medicine				china Johnson, Mohammad Heidaran, Safa	
		Conclusion	18		Kara	ndish, Lynne Boxer, Michael Mendicino, Dia	na
		rences	18		You	n, Lori Tull, Judith Arcidiacono, Brent McCrig	ght,
					Davi	d S. Kaplan, Donald Fink, Charles N. Durfor,	
3.	Cell	Banking: Process Development			Rich	ard McFarland and Celia Witten	
		Cell Preservation	21		1.	Introduction and Chapter Overview	49
						Brief Legislative History of FDA	50
	Salen	n Akel				Roles of Laws, Regulations, and Guidance	51
	Ī.	Introduction	21			FDA Organizational Structure and	51
		Product Characterization and Release			1 7 .	Jurisdictional Processes	51
		Specifications	22		V	Approval Mechanisms and Clinical Studies	52
		-h			٧.	approvariate chambins and chinear studies	32

	VI.	Meetings with Industry, Professional Groups,		Sec	ctio	n II	
		and Sponsors	54	Ste	m (	Cells and Cell Therapy	
	VII.	Regulations and Guidance of Special		O CC		sens and cen merapy	
		Interest for Regenerative Medicine	54	7.	Cel	l Therapy Landscape: Autologous	
		Human Cells and Tissues Intended for				Allogeneic Approaches	87
		Transplantation	54		anc	Allogenete Approaches	07
		Human Cellular Therapies	56		Nafe	ees N. Malik and Matthew B. Durdy	
		Gene Therapy	57		1	Introduction	87
		Xenotransplantation	57			Comparison of Commercial Potential	0/
		Cell Banking	58		11.		
		Biomaterials	59			between Autologous and Allogeneic Cell	00
		Cell-Based Combination Products:				Therapy	88
		Considerations for Product				Immunological Issues	88
		Characterization and Testing	60			Patient-Centric Factors	90
	VIII.	Preclinical Development Plan	61			Commercial-Scale Manufacturing	90
	IX.	Clinical Development Plan	62			Business Models	92
	X.	Special Topic 1: Current Good				Reimbursement Price Potential	93
		Manufacturing Practices	63		m	Key Message	96
	XI.				ш.	Future Product Commercialization:	
		Manipulated, Unrelated Allogeneic Cord				Will Allogeneic or Autologous Cell	-
		Blood	63			Therapy Dominate?	98
	XII.	Special Topic 3: Animal Cell-Based				Clinical Trials	98
		Products for Veterinary Applications	64			,	100
	XIII.	Use of Standards in Regenerative Medicine	64				103
		Advisory Committee Meetings	66				103
		FDA Regulatory Science Research					104
		Initiatives and Critical Path	66			O .	104
	XVI.	Other Communication Efforts	68		Refe	erences	104
		Conclusion	69	8	Sto	m Cells and Cell Therapy:	
		owledgment	69	0.			107
		rences	69		Au	tologous Cell Manufacturing	107
	110101		03		Ron	nda L. Bartel	
5.	New	born Stem Cell Banking Business			T.	Autologous Thorony	100
	Mod		75			Autologous Therapy	108
	14100	1013	13			Bone Marrow Aspiration	108
	Thon	nas Moore, Matthew P. Brown, John R.				Manufacturing	109
	Chap	man, Jesse Kramer, Robert P. Pfotenhauer				Allogeneic Therapy	110
	and F	Heather L. Brown				Manufacturing	111
	- 1	Introduction	75			Summary	111
		Introduction	75		кете	erences	111
	II.	Cell Biobanking History	76	9.	Ov	erview: Challenges of Process	
	III.	Public NSC Biobanking	77				113
	IV.	Family NSC Biobanking	77		DC	velopilient for Cendial Therapy	113
	V.	Operational Execution and Risk Management			Rob	ert Perry	
	VI.	Unit Quality	79	4.0	~.	F 1 1 B 11	
	VII.	Unit Storage Maintenance	79	10.		sue Engineering: Propagation	
	VIII.	Risk Mitigation Strategies	80		and	d Potency Evaluation	117
	IX.	Market Potential	80		Ivar	N. Rich	
		Competition	80				
		Scalability	80		1.	Introduction: The State of Stem Cell	
			80			Potency Evaluation	117
		Hybrid NSC Biobanking Business Models	82		11.	Developing a Reliable Potency Assay	-9.75
		The Future of NSC Biobanking	82			with Clinical Relevance	120
	Acro	The state of the s	83			A Quantitative and Validated Readout System	
	Keter	rences	83			that Measures Biological Function	120

	III.	Identification and Specific Measurement of the Active Stem Cell Components Establishment of a Reference Standard The Future of Stem Cell Potency Enumeration Frences	120 121	VII. List	Determining Regulatory Pathway Regulatory Process Conclusion Key Points of Acronyms and Abbreviations erences	146 147 148 148 148 148
		n III terials in Regenerative Medic	cine	Cha	materials in Regenerative Medicine allenges in Technology Transfer fror ence to Process Development	
				Prai	fulla Chandra, James J. Yoo and Sang Jin Lee	9
11.		materials in Preclinical Approach Engineering Skeletal Tissues	es 127	I. II.	Introduction Transfer of Biomaterials Technology from Laboratory to Commercial Production:	151
		cia T. Rodrigues, Pedro P. Carvalho, Juela E. Gomes and Rui L. Reis			Technical Considerations  Materials Selection and Design	1 <b>5</b> 3
		Introduction to Skeletal Tissue Engineering (STE)	127		Complete Product Characterization Safety and Efficacy Testing (Preclinical and	154
	II.	Biomaterials for Translational Regenerative Medicine	128		Clinical Studies) Manufacturing Considerations/Process	154
		Progression in Scaffold Development and	100		Development	156
		Fabrication Techniques Role of Synthetic- and Natural-Based Scaff	128 olds	III.	Transfer of Technology from Science to Commercial Production: Current Challenges	: 157
		in TE and Regenerative Medicine	128		Key Product Development Challenges in	, 137
		3D Templates—Scaffolds and Hydrogels	130		Academia	157
	Ш.	Could Bioreactors be the Missing Link fo	r		Key Industrial Product and Process	
		Biomechanic Function?	135	Section 1	Development Challenges	157
		Scale-Up and Ready to Go Systems	136	IV.	Options for Enabling Successful Transition	n
		Future Outcomes/Challenges	136 137		of Technology from Science to Commercialization to Clinical Use	162
		of Acronyms and Abbreviations erences	137		Role of Academia in Biomaterial Translation	
	Kere	erences	137		Research and Product Development	162
12.	Bio	materials in Regenerative Medici	ne:		Academic–Industry Partnership	162
	Co	nsiderations in Early Process			Controlling the Source and Nature of the	
	De	velopment	141		Starting Materials	162
		xander M. Tatara, Anthony Ratcliffe, Mark ng, F. Kurtis Kasper and Antonios G. Miko			Addressing Issues with Scale-Up, Process Comparability, and Process	
					Characterization	162
	I.	Introduction Assembling a Design Team	141 142		The Quality by Design Approach: Establishin	g
	111.	Key Areas of Expertise	142		Appropriate Process Controls for Unique Products and/or Manufacturing Processes	162
		Communication	142		Incorporating Process Analytical Technolog	
	Ш.	Identifying an Unmet Problem	143		into Overall Strategy	163
		Confirming a Clinical Need	143		Developing Manufacturing Technology	100
		Market Evaluation	143		Based on Closed Systems Using Closed	
		Patent Landscaping	143		Consumables	163
	IV.	Biomaterial-Specific Considerations	144		Developing Standards for Tissue	
		Product Complexity	144		Engineered and Regenerative Medicine	
		Desired Material Properties	145	1914	Products	164
		Material Manufacturing and Logistical	145	V.	Additional Considerations for Process	
		Considerations Proclinical Testing	145 146		Development for Biomaterial-Based	16
	V.	Preclinical Testing Regulatory Challenges	146	1/1	Products Summary	164 164
	٧.	regulatory chancinges	. 10	v I .	Julillary	10

	Ackı	her Reading nowledgment erences	165 165 165	111		What Will You Sell? Choosing a Business Model Select the Right Business Model for Your	188
17	Dar	acrino Pogulation from Tissuo				Product	188
17.		acrine Regulation from Tissue	169			Categories of Products	188
	LIIg	ineered Constructs	109	IV/		Academic–Business Synergy	191
	Or (	Gadish and Elazer R. Edelman		IV		Divide and Conquer: A Case Study in	102
	1.	Introduction	169			Licensing Focused Fields of Use	192
	1.	Replacing Structure	169			Early Days of HA Modification The sECM Technology	192 192
		Replacing Function	170	V		The Translational Imperative: Deliver	192
		Paracrine Tissue Engineering: Local	17.0	•	•	Simplicity	194
		Functional Augmentation	170	Re	efe	rences	194
	11.	The Development of Endothelial Cell–Bar					
		Paracrine Tissue Engineering Solutions	170				
		Case #1: Endothelial Cells Regulate		C = = 4	81	- 11/	
		Vascular Repair	172	Sect			
		Case #2: Endothelial Cells Regulate		Tissu	le	Engineering	
		Cardiomyocyte Regeneration	173	16 A	12	nufacturing of Regenerative	
		Case #3: Endothelial Cells Regulate				dicine Products	199
		Cancer	175				133
		Case #4: Endothelial Cells Regulate Bone		T	on	Spencer and Deepak Jain	
		Regeneration	175		١.	Introduction	199
		Case #5: Matrix-Embedded Cells and		1	١.	Manufacturing Process	200
		Mechanical Airway Injury	177			Step 1: Tissue Collection at the Medical	
	ш.	Designing Paracrine Tissue Engineering	170			Facility	200
		Constructs The Cells	179			Step 2: Tissue Packaging and Shipping	201
			179			Step 3: Tissue Processing and Cell Isolation	201
		Cell Source: Vanaganais, Alleganais, or	179			Step 4: Cell Expansion	202
		Cell Source: Xenogeneic, Allogeneic, or Autologous?	180			Step 5: Cell Cryopreservation	202
		Degree of Differentiation	180			Step 6: Cell Selection	203
		The Microenvironment	180			Step 7: Biomaterial Preparation	203
		Fabrication of Constructs	181			Step 8: Final Product Formulation	204
	IV.	Implications of Paracrine Tissue				Step 9: Product Filling and Packaging	204
		Engineering in Clinical Study Design	181			Step 10: Product Release	204
	V.	Conclusion	181			Step 11: Shipping and Receipt at the Medica Facility	205
		erences	182	11	r.	Manufacturing Facilities and Process	203
					1,	Equipment	205
15.	Cre	eating Commercial Value from				Facility Layout	205
	Bic	omaterials	185			Heating, Ventilation, and Air Conditioning	200
	Clo	nn D. Prestwich and Brenda K. Mann				Controls	205
	Gie					Facility Operational Controls	207
	I.	Facing Reality: An Introduction to		17	V.	Cost of Goods	208
		Translational Medicine and		,	V.	Good Manufacturing Practices, Good	
		Commercialization	185			Tissue Practices, and Quality Systems	208
		Commercialization Is Not Just Another	105	V	1.	Conclusions	210
		Research Project	185	R	efe	erences	210
		Translational Medicine Must Always	10/	47 5		mulata mu A ama ata	044
	11	Focus on the Clinical Problem What Features Do You Really Need?	186	17. 1	(e	gulatory Aspects	211
	11.	What Features Do You Really Need?  Developing the Biomaterial	187	J	oy	ce L. Frey-Vasconcells	
		Technical Scientific Criteria	187			Introduction	21
		Market, or Real-World, Criteria	188			Regulatory Path	21
					-		

<ul><li>III. Manufacturing Con</li><li>IV. Preclinical Consider</li><li>V. Clinical Trial Design</li></ul>	rations	212 215 216		nslational Animal Models for generative Medicine Research	243
VI. Developmental Cha		217	John	G. Sharp	
VII. Conclusions		218	1.	Introduction	243
References		218	П.	Brief History of Translational Animal	
18. Global Design for (	Clinical Trials	221		Models for Regenerative Medicine Research	ch
	omical mais			with an Emphasis on Hematopoietic and	
Yoshito Ikada				Immune System Regeneration	244
I. Tissue Engineering	and Regenerative			Musculoskeletal Tissue Engineering	245
Medicine		221		Soft Tissue Regeneration Ocular and Brain Repair and Regeneration	246 246
II. Follow-Up Studies	on Clinical Trials of			Heart Muscle and Vascular Regeneration	247
Tissue Engineering		222		Lung Regeneration	248
Blood Vessels of Lar		222		Engineered Intestinal, Liver, and Pancreas	210
Blood Vessels of Sm	all Diameter	224		Regeneration	249
Mandibular Bone Orbital Floor		224 226	IX.	Urogenital Repair and Bladder Tissue	
III. Topics on Scaffold		226		Engineering	250
Importance of Scaffe	old	227	Χ.	Future Approaches: Stem Cells, Repro-	
Scaffold with iPS Ce		227		grammed Cells, and Immunodeficient and	
Cell-Free Scaffold		228		Humanized Mouse Models for Tissue	254
Scaffolds for Large (	Organs	229	ΥI	Regeneration Pros and Cons of Translational Animal	251
IV. Global Design for O	Clinical Trials of Tissue		AI.	Models for Regenerative Medicine Research	252
Engineering		230	Acro	onyms and Abbreviations	253
References		231		nowledgments	253
			Refe	rences	253
			21 Tra	nslational Imaging for	
Section V				generative Medicine	257
Enabling Tools					237
			Sne	ha S. Kelkar and Aaron M. Mohs	
19. Biomarkers		235	I.	Introduction	257
Ralf Huss				Contrast Agents	257
		005		Ultrasound	258
I. Introduction	Deleted Blancadion	235		X-ray CT	259
<ul><li>II. Disease- and Drug</li><li>III. Biomarkers in Drug</li></ul>	-Related Biomarkers	236 236		Nuclear Imaging	259
IV. Biomarker Require	-	237		Magnetic Resonance Imaging Multimodal Imaging	260 263
V. Biomarker Classific		207		Summary	263
Application		237		erences	263
VI. Discovery of Mole	cular Biomarkers	238			
Genomics Approac		238			
Proteomics Approac		238	Section	yn VI	
Metabolomics Appr		238	100		
Lipidomics Approac		238		al Aspects of Regenerative	
Tissue-Based Bioma		238 239	Medic	rine	
Imaging Biomarkers VII. Surrogate End Poir		237	22. <b>S</b> ki	n and Skin Appendage	
Disadvantages	no and rotential	239		generation	269
VIII. Biomarker in Rege	nerative Medicine	239			
XI. Quality Manageme		240	Krz	ysztof Kobielak, Eve Kandyba and Yvonne Le	eung
X. Personalized Medi		240		Introduction	269
References		241		Epidermis	271

		Epidermal Stem Cells Models	271			Rehabilitation Following Injection	
		Human Epidermal Stem Cells (EpiSCs)	273			Procedures	304
		Epidermal Regeneration from Cultured			IV.	Discussion	305
		Keratinocytes	273		V.	Practical Considerations	306
		Alternative Sources of Stem Cells in				Adjunctive Therapy	306
		Epidermal Regeneration	274		VI.	Summary	307
	III.	Hair Follicle and Sebaceous Gland	276			erences	307
		Hair Follicle and Sebaceous Gland					
		Structure and Function	276	0.4	n	D	242
		Hair Follicle Stem Cells (HFSCs)	276	24.	RO	ne Regeneration	313
		Hair Germ (HG)	278		Suz	anne Stewart, Stephanie J. Bryant,	
		Role of Hair Follicles in Skin				no Ahn and Kurt D. Hankenson	
		Regeneration	278				
		Niche Components of Hair Follicle Stem			l.	Clinical Importance of Bone Healing	313
		Cells and Hair Germ	279			Bone Healing is Regeneration	313
		Intrinsic (Intrabulge) and Extrinsic (Niche	2.0			The Magnitude and Importance of Fractures	313
		Environment) Signaling in Hair Follicle				Limitations and Goals of Treatment	314
		Stem Cells and Hair Regeneration	280		11.	Basic Biology of Bone Healing	314
		Intra-Stem Cell Antagonistic Competition	200			Structure of Bone	314
		between BMP and Wnt Signaling				Formation of Bone	316
		Balances Stem Cell Activity	282		Ш.	Bone Regeneration	317
	IV	Sweat Gland	282			Bone Healing	317
	IV.	Structure and Function	282			Deficiencies in Bone Healing—What Do	
		Sweat Gland Disorders	284			We Hope to Accomplish with	
		Sweat Glands in Wound Healing	284			Therapeutics?	318
		Sweat Gland Stem Cells and Their	201		IV.	Current and Future Repair	
		Multipotency in Regeneration of the				Strategies	318
		Epidermis, Sweat Glands, and Hair				Fixation Rationale and	
		Follicles	284			Methodologies	318
	V	Future Challenges in Skin Regeneration	285			Bone Grafts	320
		nowledgments	286			Engineered Biomaterials	321
		erences	286			Biological Factors	324
	Ken	erences	200			Antibiotic Delivery	326
					V.	Conclusions	327
23	Cli	nical Aspects of Regenerative			Ref	erences	328
20,		edicine: Tendon, Ligament,					
			202	25	Po	generative Medicine Therapies	
	ano	d Joint	293	4.0.			225
	Ste	ven Sampson, Angie Botto-van Bemden			US	ing Adipose-Derived Stem Cells	335
		Danielle Aufiero			Jole	ene E. Valentin, Albert D. Donnenberg,	
		1-1-1-2	202		Kad	cey G. Marra and J. Peter Rubin	
	Į.	Introduction	293			Alleres Desired Come Cells for Theorem	225
	П.	Platelet-Rich Plasma	294		I.	and the second s	335
		What Is It?	294		11.	0 /	336
		Clinical Application of PRP	294		Ш.	Current Clinical Trials and Evolving	227
		Variations in PRP Preparations	297			Potential	337
		Current PRP Injection Applications	298			Cell Delivery to Zones of Injury	337
	Ш.		300		13.7	ASCs in Tissue Engineering	337
		What Is It?	300			Methods of Lipoharvest	340
		Clinical Application of Autologous	201		V.	Methods of SVF Isolation: Automated	2.40
		BMC	301		3.71	versus Manual	340
		Safety Considerations with BMC	202			Flow Cytometry Analysis	343
		Therapy	303			Concluding Remarks	343
		Clinical Support of BMSC Therapy in	202			t of Abbreviations	343
		Patients with Joint Pathology	303		Kei	ferences	343